Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection

Recombinant human immunoglobulin molecules neutralizing for HIV-1, methods of production of the immunoglobulins and methods of preventing HIV-1 infection using the immunoglobulins are disclosed. DNA constructs containing the complementarity determining regions (CDRs) and framework (FRs) of the nativ...

Full description

Saved in:
Bibliographic Details
Main Authors MARK, GEORGE E, EMINI, EMILIO A, PFARR, DAVID S, CONLEY, ANTHONY J, JOHNSON, L. SYD
Format Patent
LanguageEnglish
French
German
Published 02.11.1994
Edition5
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES USING MICROORGANISMS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Recombinant human immunoglobulin molecules neutralizing for HIV-1, methods of production of the immunoglobulins and methods of preventing HIV-1 infection using the immunoglobulins are disclosed. DNA constructs containing the complementarity determining regions (CDRs) and framework (FRs) of the native human antibody are combined with other constant regions, and expressed in recombinant host cells. These recombinant antibodies are useful for the treatment and prevention of HIV-1 infection in vivo.
Bibliography:Application Number: EP19930302546